Literature DB >> 1993623

Conformal static field therapy for low volume low grade prostate cancer with rigid immobilization.

E M Soffen1, G E Hanks, C C Hwang, J C Chu.   

Abstract

The ability to improve existing standards of treating prostate cancer was investigated. To deliver a homogenous dose to the prostate with as little normal tissue margin as practical, seven patients with low volume carcinoma of the prostate were immobilized with alpha cradle body casts prior to using a CT-based 3D treatment planning system and beam's eye view (BEV) template. All patients had clinical Stage B-1 prostate cancer of favorable histologic differentiation (Gleason Score 2-5). A four field box technique was used, each beam having a single customized cerrobend block cut-out conforming to the exact contour of the prostate. To assess the accuracy of this process, daily port films were taken for 5 consecutive days and compared to a matched control group who were treated in a similar fashion, but were not casted. Dose volume histograms illustrate an average of 14% of bladder dose and 14% of rectal dose that can be eliminated using this technique when compared to field sizes and block placement in our previous technique. Daily setup variation was markedly improved using the cast, with a median daily variation of 1 mm as compared to 3 mm without the cast. The average range of movement for each of the seven casted patients was 3.3 mm as compared to 8 mm for the seven uncasted patients. Immobilization eliminated the worst 10% of all daily positioning errors. Using CT treatment planning with the patient casted and BEV allows for precise block placement with the prostate gland in its proper orientation during daily treatment. With improved immobilization and precise localization of the prostate gland, margins around the target can be made significantly smaller, and this may translate into a decrease in acute and/or late complications.

Entities:  

Mesh:

Year:  1991        PMID: 1993623     DOI: 10.1016/0360-3016(91)90150-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  [Planned 3-dimensional low-volume conformal irradiation of a local prostatic carcinoma].

Authors:  S Wachter; N Gerstner; K Dieckmann; M Stampfer; R Hawliczek; R Pötter
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

2.  [Virtual simulation. First clinical results in patients with prostate cancer].

Authors:  A Buchali; S Dinges; S Koswig; P Rosenthal; S Salk; C Harder; L Schlenger; V Budach
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

Review 3.  Adaptive radiation therapy for prostate cancer.

Authors:  Michel Ghilezan; Di Yan; Alvaro Martinez
Journal:  Semin Radiat Oncol       Date:  2010-04       Impact factor: 5.934

4.  Comparison of the effectiveness of different immobilization systems in different body regions using daily megavoltage CT in helical tomotherapy.

Authors:  K-F Cheng; V W C Wu
Journal:  Br J Radiol       Date:  2014-01-07       Impact factor: 3.039

5.  [The conformal radiotherapy of localized prostatic carcinoma: acute tolerance and early efficacy].

Authors:  D Zierhut; M Flentje; G Sroka-Perez; V Rudat; R Engenhart-Cabillic; M Wannenmacher
Journal:  Strahlenther Onkol       Date:  1997-02       Impact factor: 4.033

6.  A clinical evaluation of setup errors for a prostate immobilization system.

Authors:  J E McGary; W Grant
Journal:  J Appl Clin Med Phys       Date:  2000       Impact factor: 2.102

Review 7.  Image-guided radiotherapy for prostate cancer.

Authors:  Audrey Dang; Patrick A Kupelian; Minsong Cao; Nzhde Agazaryan; Amar U Kishan
Journal:  Transl Androl Urol       Date:  2018-06

8.  Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).

Authors:  S Stanley; S Griffiths; M R Sydes; A R Moore; I Syndikus; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06-18       Impact factor: 4.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.